|
|
1V270 |
|
Vaxjo ID |
114 |
|
Vaccine Adjuvant Name |
1V270 |
|
Adjuvant VO ID |
VO_0005270
|
|
Description |
small molecule with TLR7 receptor; induces mucosal immunity, CD8 t-cells, epitope spreading; provides innate protection, antibody affinity maturation, antibody epitope spreading; triggers Th1 immune response |
|
Stage of Development |
Research |
|
Location Licensed |
US (UCSD) |
|
Host Species for Testing |
Mouse |
|
Components |
"phospholipid conjugated small molecule TLR7 ligand = 1V270 small molecule TLR4 agonist = 2B182C " |
|
Storage |
"Formulated 1V270 at 4C for 6 months Solid form is stable at 4C for > 2 years" |
|
Preparation |
liposomal combination of 1V270 and 2B182C --> both things were co-encapsulated in liposomes, and these liposomal formulations were prepared by the lipid film rehydration method using DOPC:cholesterol in a molar ratio of 2:1 (1V270: 2B182C) |
|
Function |
Type: TLR agonist vaccine adjuvant. Target Receptor: Toll-like receptor 7 (TLR7). Induces Th1-biased immune profile. activates innate immune pathways, specifically against influenza |
| Related Vaccine(s) |
|
| References |
(Carson, 2021): Vaccine Adjuvant Compendium (VAC) [https://vac.niaid.nih.gov/view?id=6]
Sato-Kaneko et al., 2020: Sato-Kaneko F, Yao S, Lao FS, Shpigelman J, Messer K, Pu M, Shukla NM, Cottam HB, Chan M, Chu PJ, Burkhart D, Schoener R, Matsutani T, Carson DA, Corr M, Hayashi T. A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity. Frontiers in immunology. 2020; 11; 1207. [PubMed: 32636840].
|
|
